In clinical trials (NCT01523821 and NCT01700036), AAT treatment increased the proportion of Tregs and reduced GVHD manifestations (67), while decreasing numbers of CD8+ TM cells (68) in steroid refractory (SR) GVHD patients without clinical toxicity. Here, CD8A is linked to graft versus host disease.